HYDROQUINONE- hydroquinone cream TWi Pharmaceuticals, Inc.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Hydroquinone USP, 4% Skin Bleaching Cream Rx Only FOR EXTERNAL USE ONLY NOT FOR OPHTHALMIC USE

DESCRIPTION

Each gram of Hydroquinone USP, 4% Skin Bleaching Cream contains 40 mg hydroquinone USP, in a vanishing cream base of glyceryl monostearate, mineral oil, PEG-25 propylene glycol stearate, polyoxyl 40 stearate, propylene glycol, propylparaben, purified water, sodium metabisulfite, squalane and stearic acid. Chemically, hydroquinone is $C_6H_6O_2$ and has a molecular weight of 110.11.

The chemical name is 1,4 dihydroxybenzene, and the structural formula of hydroquinone is:



CLINICAL PHARMACOLOGY

Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3,4-dihydroxyphenylalanine (dopa) (Denton, C. et al., 1952)¹ and suppression of other melanocyte metabolic processes (Jimbow, K. et al., 1974)². Exposure to sunlight or ultraviolet light will cause repigmentation of bleached areas (Parrish, J.A. et al., 1978)³.

INDICATIONS AND USAGE

Hydroquinone USP, 4% Skin Bleaching Cream is indicated for the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.

CONTRAINDICATIONS

Prior history of sensitivity or allergic reaction to hydroquinone or to any of the ingredients of the product. The safety of topical hydroquinone use during pregnancy or for children (12 years and under) has not been established.

WARNINGS

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

Since this product contains no sunscreen, an effective broad spectrum sun blocking agent should be used and unnecessary solar exposure avoided, or protective clothing should be worn to cover bleached skin in order to prevent repigmentation from occurring.

Hydroquinone may produce exogenous ochronosis, a gradual blue-black darkening of the skin. If this condition occurs, discontinue treatment and consult your physician. The majority of patients developing this condition are Black, but it may also occur in Caucasians and Hispanics.

PRECAUTIONS

(see WARNINGS)

General -

Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin; check within 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response further treatment is not advised. Close patient supervision is recommended.

Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication.

Information for Patients -

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight sustains melanocytic activity. To prevent repigmentation, during treatment and maintenance therapy, sun exposure on treated skin should be avoided by application of a broad spectrum sunscreen (SPF 15 or greater) or by use of protective clothing.

Avoid contact with eyes and mucous membranes.

Keep this and all medications out of reach of children. In case of accidental ingestion, call a physician or a poison control center immediately.

Drug Interactions -

Patients are cautioned on concomitant use of medications that are known to be photosensitizing.

Carcinogenesis, Mutagenesis, Impairment of Fertility -

Studies of hydroquinone in animals have demonstrated some evidence of carcinogenicity. The carcinogenic potential of hydroquinone in humans is unknown.

Published studies have demonstrated that hydroquinone is a mutagen and a clastogen. Treatment with hydroquinone has resulted in positive findings for genetic toxicity in the Ames assay in bacterial strains sensitive to oxidizing mutagens, in *in vitro* studies in mammalian cells, and in the *in vivo* mouse micronucleus assay.

Pregnancy:

Teratogenic Effects:

Pregnancy Category C -

Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether topical hydroquinone can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Topical hydroquinone should be given to a pregnant woman only if clearly needed.

Nursing Mothers -

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when topical hydroquinone is administered to a nursing woman.

Pediatric Use -

Safety and effectiveness for pediatric patients below the age of 12 years have not been established.

ADVERSE REACTIONS

The following adverse reactions have been reported: dryness and fissuring of paranasal and infraorbital areas, erythema, and stinging. Occasional hypersensitivity (localized contact dermatitis) may develop. If this occurs, the medication should be discontinued and the physician notified immediately.

OVERDOSAGE

There have been no systemic reactions reported from the use of topical hydroquinone. However, treatment should be limited to relatively small areas of the body at one time, since some patients experience a transient skin reddening and a mild burning sensation which does not preclude treatment.

DOSAGE AND ADMINISTRATION

Hydroquinone USP, 4% Skin Bleaching Cream should be applied to affected areas and rubbed in well twice daily, in the morning and before bedtime, or as directed by a physician. If no improvement is seen after 2 months of treatment, use of this product should be discontinued. There is no recommended dosage for pediatric patients under 12 years of age except under the advice and supervision of a physician.

HOW SUPPLIED

Hydroquinone USP, 4% Skin Bleaching Cream is available as follows:

1 oz (28.35 g) tube (NDC 24979-**141**-36)

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

REFERENCES

1 DENTON C., LERNER A.B., FITZPATRICK T.B.

Inhibition of Melanin Formation by Chemical Agents

Journal of Investigative Dermatology 1952, 18:119-135.

2 JIMBOW K., OBATA H., PATHAK M., FITZPATRICK T.B.

Mechanism of Depigmentation by Hydroquinone

Journal of Investigative Dermatology 1974, 62:436-449.

3 PARRISH J.A., ANDERSON R.R., URBACH F., PITTS D.

UVA, Biological Effects of Ultraviolet Radiation with Emphasis

on Human Responses to Longwave Ultraviolet

Plenum Press, New York and London, 1978, p. 151. Manufactured for: TWi pharmaceuticals USA, Inc. Paramus, NJ 07652 Manufacured by: Aphena Pharma Solutions, Easton, MD 21601 Rev 01-19


Principal Display Panel - 1 oz Carton

Rx Only NDC 24979-141-36 Hydroquinone USP, 4% Skin Bleaching Cream Net Wt 1 oz (28.35 g)



Principal Display Panel - 1 oz Tube

Rx Only NDC 24979-141-36 Hydroquinone USP, 4% Skin Bleaching Cream Net Wt 1 oz (28.35 g)



-						
Product Information Item Code (Source) NDC:24979-141 Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:24979-141 Route of Administration TOPICAL V V V Active Ingredient/Active Mo V V V V Active Ingredient/Active MoU V V V V V Active Ingredient/Active MoU V Basis of Street Strength HYDROQUINONE (UNIE XV74C1N1AE) (HYDROQUINONE - UNIEXV74C1N1AE) HYDROQUINONE 40 mg in 1 g Inactive Ingredients Ingredient Name V V 40 mg in 1 g GLYCERYL MONOSTEARATE (UNIE 3UOU9XXE4) TIngredient Name V V V MINERAL OIL (UNIE 75L8728FGP) V V V V V POLYOXYL 40 STEARATE (UNIE 13J4VHNP1) V V V V V V	HYDROQUINONE					
Product TypeHUMAN PRESCRIPTION DRUGHem Code (Source)Del CalueeRoute of AdministrationTOPICALSource)Source)Active Ingredient/Active MotorSource)StengthHYDROQUINONE (UNE: XV74C1N1AE)HYDROQUINONE - UNE: XV74C1N1AE)HYDROQUINONE (Source)More in 19Inactive IngredientsStengthStengthGLYCERYL MONOSTEARATE (UNE: SUGUEXCE)StengthStengthMINERAL OLI (UNI: T5L8128 FGP)StengthStengthPOLYOXYL 40 STEARATE (UNI: SUGUEXCE)StengthStength	hydroquinone cream					
Product TypeHUMAN PRESCRIPTION DRUGHem Code (Source)Del CalueeRoute of AdministrationTOPICALSource)Source)Active Ingredient/Active MotorSource)StengthHYDROQUINONE (UNE: XV74C1N1AE)HYDROQUINONE - UNE: XV74C1N1AE)HYDROQUINONE (Source)More in 19Inactive IngredientsStengthStengthGLYCERYL MONOSTEARATE (UNE: SUGUEXCE)StengthStengthMINERAL OLI (UNI: T5L8128 FGP)StengthStengthPOLYOXYL 40 STEARATE (UNI: SUGUEXCE)StengthStength						
Route of Administration TOPICAL Active Ingredient/Active Moission Basis of Strength Ingredient Name Basis of Strength HyDROQUINONE (UNII: XV74C1N1AE) HYDROQUINONE - UNII:XV74C1N1AE) Hydroquinone (UNII: SV74C1N1AE) Ingredient Name Strength GLYCERYL MONOSTEARATE (UNII: 230-009XXE4) Strength MINERAL OIL (UNII: T5L8728FGP) Strength	Product Information					
Active Ingredient/Active Moiety Basis of Strength Strength HYDROQUINONE (UNII: XV74C1N1AE) (HYDROQUINONE - UNII:XV74C1N1AE) HYDROQUINONE 40 mg in 1 g HYDROQUINONE (UNII: XV74C1N1AE) (HYDROQUINONE - UNII:XV74C1N1AE) HYDROQUINONE 40 mg in 1 g Inactive Ingredients Strength GLYCERYL MONOSTEARATE (UNII: 2300U9XXE4) Strength MINERAL OIL (UNII: T5L8T28FGP) POLYOXYL 40 STEARATE (UNII: 13A4J4NH9J)	Product T ype	HUMAN PRESCRIPTION DRUG	Ite m Cod e	(Source)	NDC:	24979-141
Ingredient NameBasis of StrengthStrengthHYDROQUINONE (UNII: XV74C1N1AE) (HYDROQUINONE - UNII:XV74C1N1AE)HYDROQUINONE40 mg in 1 gInactive IngredientsIngredient NameStrengthGLYCERYL MONOSTEARATE (UNII: 2300U9XXE4)StrengthStrengthMINERAL OIL (UNII: T5L8 T28 FGP)Steanate (UNII: 13A4J4NH91)I	Route of Administration	TOPICAL				
Ingredient NameBasis of StrengthStrengthHYDRO QUINO NE (UNII: XV74C1N1AE) (HYDRO QUINO NE - UNII: XV74C1N1AE)HYDRO QUINO NE40 mg in 1 gInactive IngredientsIngredient NameStrengthGLYCERYL MONOSTEARATE (UNII: 230 OU9 XXE4)StrengthStrengthMINERAL O IL (UNII: T5L8 T28 FGP)POLYO XYL 40 STEARATE (UNII: 13A4J4NH91)I						
Ingredient NameBasis of StrengthStrengthHYDRO QUINO NE (UNII: XV74C1N1AE) (HYDRO QUINO NE - UNII: XV74C1N1AE)HYDRO QUINO NE40 mg in 1 gInactive IngredientsIngredient NameStrengthGLYCERYL MONOSTEARATE (UNII: 230 OU9 XXE4)StrengthStrengthMINERAL O IL (UNII: T5L8 T28 FGP)POLYO XYL 40 STEARATE (UNII: 13A4J4NH91)I						
HYDROQUINONE (UNII: XV74C1N1AE) (HYDROQUINONE - UNII: XV74C1N1AE) HYDROQUINONE 40 mg in 1 g Inactive Ingredients Ingredient Name Strength GLYCERYL MONOSTEARATE (UNII: 2300U9XXE4) Imineral oil (UNII: 7518728FGP) Imineral oil (UNII: 13A4J4NH91) POLYOXYL 40 STEARATE (UNII: 13A4J4NH91) Imineral oil (UNII: 13A4J4NH91) Imineral oil (UNII: 13A4J4NH91)	Active Ingredient/Active Moi	ety				
Inactive Ingredients Ingredient Name Strength GLYCERYL MONOSTEARATE (UNII: 230 OU9 XXE4) MINERAL OIL (UNII: 75L8 T28 FGP) POLYOXYL 40 STEARATE (UNII: 13A4J4NH91)	Ingredient Name Basis of Streng					Strength
Ingredient NameStrengthGLYCERYL MONOSTEARATE (UNII: 2300U9XXE4)MINERAL OIL (UNII: T5L8T28FGP)POLYOXYL 40 STEARATE (UNII: 13A4J4NH91)	HYDROQUINONE (UNII: XV74C1N1AE	E) (HYDROQUINONE - UNII:XV74C1N1AE))	HYDROQUINONE		40 mg in 1 g
Ingredient NameStrengthGLYCERYL MONOSTEARATE (UNII: 2300U9XXE4)MINERAL OIL (UNII: T5L8T28FGP)POLYOXYL 40 STEARATE (UNII: 13A4J4NH91)						
Ingredient NameStrengthGLYCERYL MONOSTEARATE (UNII: 2300U9XXE4)MINERAL OIL (UNII: T5L8T28FGP)POLYOXYL 40 STEARATE (UNII: 13A4J4NH91)						
GLYCERYL MONOSTEARATE (UNII: 230 OU9 XXE4)Image: Comparison of the second s	Inactive Ingredients					
MINERAL OIL (UNII: T5L8T28FGP) POLYOXYL 40 STEARATE (UNII: 13A4J4NH91)		Ingredient Name				Strength
POLYOXYL 40 STEARATE (UNII: 13A4J4NH9I)	GLYCERYL MONOSTEARATE (UNII:	230 O U9 XXE4)				
	MINERAL OIL (UNII: T5L8T28FGP)					
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	POLYOXYL 40 STEARATE (UNII: 13A	A4J4NH9I)				
	PROPYLENE GLYCOL (UNII: 6DC9Q	167V3)				

	ROPYLPARABEN (U	JNII: Z8IX2SC1OH)					
W	WATER (UNII: 059QF0KO0R)						
s	SODIUM METABISULFITE (UNII: 4VON5FNS3C)						
S	SQUALANE (UNII: GW89575KF9)						
S	FEARIC ACID (UNII:	4ELV7Z65AP)					
PI	EG-25 PROPYLENE	GLYCOL STEARATE (UNII: X21KPH4633)					
Product Characteristics							
Color WHITE (white to off-white)				Score			
Shape			Size				
Fl	avor			Imprint Code			
С	ontains						
Р	ackaging						
P #	ackaging Item Code	Package Description	Mark	eting Start Date	Marketing End	l Date	
#		Package Description 1 in 1 CARTON	Mark 06/16/2	0	Marketing End	l Date	
#	Item Code	. .		0	Marketing End	l Date	
# 1	Item Code	1 in 1 CARTON		0	Marketing End	l Date	
# 1	Item Code	1 in 1 CARTON		0	Marketing End	l Date	
# 1 1	Item Code NDC:24979-141-36	1 in 1 CARTON 28.35 g in 1 TUBE; Type 0: Not a Combination Product		0	Marketing End	l Date	
# 1 1	Item Code NDC:24979-141-36	1 in 1 CARTON 28.35 g in 1 TUBE; Type 0: Not a Combination Product ormation	06/16/2	20 17			
# 1 1	Item Code NDC:24979-141-36 Iarketing Inf Iarketing Categor	1 in 1 CARTON 28.35 g in 1 TUBE; Type 0: Not a Combination Product Ormation Application Number or Monograph Citation	06/16/2 Mark	20 17 Keting Start Date	Marketing End		
# 1 1	Item Code NDC:24979-141-36	1 in 1 CARTON 28.35 g in 1 TUBE; Type 0: Not a Combination Product Ormation Application Number or Monograph Citation	06/16/2	20 17 Keting Start Date			

Labeler - TWi Pharmaceuticals, Inc. (658402052)

Registrant - T Wi Pharmaceuticals, Inc. (658402052)

Establishment

Name	Address	ID/FEI	Business Operations
Aphena Pharma Solutions		829739833	manufacture(24979-141), analysis(24979-141), pack(24979-141)

Revised: 1/2019

TWi Pharmaceuticals, Inc.